SillaJen Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SillaJen's estimated annual revenue is currently $5.3M per year.(i)
  • SillaJen's estimated revenue per employee is $155,000

Employee Data

  • SillaJen has 34 Employees.(i)
  • SillaJen grew their employee count by 10% last year.

SillaJen's People

NameTitleEmail/Phone
1
COO, Head CMC.Reveal Email/Phone
2
Senior Manager, Corporate Accounting & FinanceReveal Email/Phone
3
Clinical Research Scientist/Medical Monitor (Remote)Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is SillaJen?

SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.

keywords:N/A

N/A

Total Funding

34

Number of Employees

$5.3M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M34-19%$14.2M
#2
$3.6M3417%$44M
#3
$3.9M34N/AN/A
#4
$3.6M340%$11.4M
#5
$3.8M34N/AN/A